QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping

QIAGEN N.V. (QGEN) recently entered into a collaboration to support the development of a QIAstat-Dx invitro diagnostic (IVD) panel with Eli Lilly and Company. The QIAstat-Dx panel will be used to detect apolipoprotein E (APOE) genotypes. The QIAstat-Dx panel will be the first commercially available IVD for APOE genotyping. The recent collaboration is poised to enhance the company's Molecular Diagnostics business. Shares of QGEN were up 0.4% in pre-market trading today following the news. With the company ga ...